• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

    9.360 +0.270 (+2.97%)
    Streaming Delayed Price Updated: 10:20 AM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 137,706
    Open 9.100
    Bid (Size) 9.350 (200)
    Ask (Size) 9.370 (200)
    Prev. Close 9.090
    Today's Range 9.100 - 9.550
    52wk Range 3.000 - 12.34
    Shares Outstanding 42,052,980
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +27.9%
    +27.9%
    1 Month
    -1.3%
    -1.3%
    3 Month
    +2.3%
    +2.3%
    6 Month
    -16.6%
    -16.6%
    1 Year
    +148.9%
    +148.9%

    More News

    Read More
    News headline image
    4DMT to Participate in Upcoming Investor Meetings
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease ↗
    Via Stocktwits
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Provides Company Update and Anticipated Development Milestones for 2026
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in 8th Annual Evercore Healthcare Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Appoints Kristian Humer as Chief Financial Officer
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in Jefferies 2025 London Healthcare Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock ↗
    Via Benzinga
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?
    Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?
    4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?
    The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market
    What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?
    The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 9.360
    When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?
    The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 05/04/26 10:20 AM ET
    What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?
    The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 393.62M
    How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?
    4D Molecular Therapeutics, Inc. - Common Stock has 394M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.